Rhumbline Advisers decreased its position in Cerus Corporation (NASDAQ:CERS) by 0.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 113,726 shares of the biotechnology company’s stock after selling 63 shares during the period. Rhumbline Advisers owned about 0.11% of Cerus Corporation worth $285,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in Cerus Corporation in the first quarter valued at approximately $137,000. First Manhattan Co. lifted its stake in Cerus Corporation by 31.3% in the second quarter. First Manhattan Co. now owns 42,000 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 10,000 shares during the last quarter. American International Group Inc. lifted its stake in Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 4,127 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its stake in Cerus Corporation by 7.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 81,132 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 5,920 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Cerus Corporation by 12.8% in the first quarter. Renaissance Technologies LLC now owns 92,500 shares of the biotechnology company’s stock valued at $412,000 after purchasing an additional 10,500 shares during the last quarter. Institutional investors and hedge funds own 58.33% of the company’s stock.
Shares of Cerus Corporation (CERS) opened at 3.02 on Thursday. The firm’s 50 day moving average price is $2.66 and its 200 day moving average price is $2.89. Cerus Corporation has a 52-week low of $1.93 and a 52-week high of $6.07. The stock’s market cap is $329.59 million.
Cerus Corporation (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). The business had revenue of $9.53 million for the quarter, compared to analysts’ expectations of $9.14 million. Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.18) EPS. On average, analysts expect that Cerus Corporation will post ($0.64) EPS for the current year.
WARNING: This story was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.themarketsdaily.com/2017/10/12/cerus-corporation-cers-shares-sold-by-rhumbline-advisers.html.
Several equities analysts recently commented on CERS shares. ValuEngine downgraded Cerus Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub downgraded Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Zacks Investment Research downgraded Cerus Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Finally, Cowen and Company set a $6.00 price objective on Cerus Corporation and gave the company a “buy” rating in a research note on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $7.00.
In other Cerus Corporation news, insider Laurence M. Corash purchased 92,796 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were acquired at an average price of $2.45 per share, for a total transaction of $227,350.20. Following the purchase, the insider now directly owns 1,375,711 shares of the company’s stock, valued at approximately $3,370,491.95. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 7.40% of the company’s stock.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.